Skip to main content
Search
Search
Anywhere
Quick Search anywhere
Enter words / phrases / DOI / ISBN / keywords / authors / etc
Search
Advanced Search
Login
Skip main navigation
Open Drawer Menu
Close Drawer Menu
Home
Journal of Comparative Effectiveness Research
Journal of Patient Centricity
The Evidence Base
Skip slideshow
Journal of Comparative Effectiveness Research
ISSN (print): 2042-6305 • ISSN (online): 2042-6313
Impact Factor: 2.8 (2025) • CiteScore: 4.2 (2025) • Open Access
Read more
Journal of Patient Centricity
ISSN (online): 2978-8579
In partnership with the PCSIG • Open Access
Read more
The Evidence Base
Latest news, opinion and insight into hot topics including RWE, HEOR, HTA and market access
Read more
Latest
Validation of an all-source composite mortality endpoint in the US population
Yanina Natanzon
,
Lukas Slipski
, and
Mark S Walker
Journal of Comparative Effectiveness Research
31 Aug 2026
Access in all areas? A round-up of developments in market access and health technology assessment: part 16
Sreeram V Ramagopalan
and
Annie Jullien Pannelay
Journal of Comparative Effectiveness Research
27 Aug 2026
Maprium and Vitaccess partner on managed access programs and real-world evidence
The Evidence Base
31 Aug 2026
Market access and HTA developments with Sreeram Ramagopalan: Prior authorization barriers and cost-effectiveness thresholds
The Evidence Base
28 Aug 2026
Journal of Comparative Effectiveness Research
Open access, peer-reviewed journal offering rapid publication for all aspects of HEOR and related areas
Read More
FROM THE EVIDENCE BASE
31 Aug 2026
Maprium and Vitaccess partner on managed access programs and real-world evidence
28 Aug 2026
Market access and HTA developments with Sreeram Ramagopalan: Prior authorization barriers and cost-effectiveness thresholds
26 Aug 2026
Canada’s Drug Agency issues guidance on AI-generated real-world evidence for HTA
31 Aug 2026
Maprium and Vitaccess partner on managed access programs and real-world evidence
28 Aug 2026
Market access and HTA developments with Sreeram Ramagopalan: Prior authorization barriers and cost-effectiveness thresholds
26 Aug 2026
Canada’s Drug Agency issues guidance on AI-generated real-world evidence for HTA
25 Aug 2026
We are asking the wrong question about drug prices
25 Aug 2026
WEBINAR: From scoping to systematic: Choosing the right literature review for your evidence needs – October 6, 2026
18 Aug 2026
Swiss Pharma industry calls for policy changes following US MFN pricing impact survey
The Evidence Base
Online hub providing the latest news, opinion and insights into HEOR, RWE, HTA and more
Read More
FROM THE EVIDENCE BASE
31 Aug 2026
Maprium and Vitaccess partner on managed access programs and real-world evidence
28 Aug 2026
Market access and HTA developments with Sreeram Ramagopalan: Prior authorization barriers and cost-effectiveness thresholds
27 Aug 2026
FDA outlines considerations for digitally derived measures in clinical investigations
26 Aug 2026
Canada’s Drug Agency issues guidance on AI-generated real-world evidence for HTA
.png)
.png)
